Relonchem, a Marksans Pharma subsidiary, has obtained MHRA approval for clonidine 100 µg and clonidine hydrochloride 25 µg tablets for the UK market.
Source: Marksans Pharma Press Release (NSE Exchange Fillings) | Published on Oct 15, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release of Marksans Pharma (NSE Exchange Filings), Relonchem Limited, a fully owned UK subsidiary of the company, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for two formulations of clonidine. These are clonidine 100 microgram tablets and clonidine hydrochloride 25 microgram tablets.
Also read: Adani Green Operationalises 50 MW Solar Project At Khavda, Gujarat
Relonchem receives MHRA approval for two clonidine formulations in the UK.
The development strengthens Marksans Pharma’s product range in regulated markets.
Clonidine is widely used to manage hypertension and certain related conditions.
The company continues to maintain multiple global regulatory approvals.
Also read: AstraZeneca to Launch Sodium Zirconium Cyclosilicate Suspension In November 2025
The MHRA approval permits Relonchem to manufacture, market, and sell products based on clonidine in Great Britain. This further extends the company's footprint in the cardiovascular therapy space.
Product Name | Strength | Regulatory Body | Market |
Clonidine Tablets | 100 microgram | MHRA (UK) | United Kingdom |
Clonidine Hydrochloride Tablets | 25 microgram | MHRA (UK) | United Kingdom |
Both products use clonidine as the active ingredient, which is known for its therapeutic applications in blood pressure management and related medical treatments.
Based in Mumbai, India, Marksans Pharma is involved in research, production, and sale of the generic pharmaceutical formulations. The company operates in a number of global markets and has production facilities in India, the United States and the United Kingdom.
The company facilities are compliant with regulations set forth by the US Food and Drug Administration (USFDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the Therapeutic Goods Administration (TGA). The approvals demonstrate compliance with strict quality requirements that are the standard in governed environments of pharmaceuticals.
The approval of clonidine products by Relonchem is another in a growing series of approvals from the MHRA. For many years Marksans Pharma has has consistent compliance at its manufacturing and distribution sites to the standards of global regulations in pharmaceuticals. The recent approval adds to approvals for other products approved for metformin extended release and baclofen tablets.
As of 15 Oct 2025, Marksans Pharma share price stood at ₹180.15 per share on the BSE at 15:30 PM IST. This figure reflects the market’s ongoing assessment of the company’s fundamentals, risks, and growth prospects.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading